Navigation Links
Research in fish provides new clues about deadly form of liver cancer
Date:7/4/2011

translated into a method for diagnosing the disease in humans. In addition, the stage of cancer is an important factor in determining how patients should be treated. In this study, the researchers determined genetic signatures that were specific to early- and late-stage liver cancer, which might help in planning treatment regimes for patients with HCC.

These new findings using a zebrafish model of HCC should help to guide studies of this complex cancer in humans. Although validation studies in patients with HCC are required, this work provides new evidence that drugs targeting the Ras pathway are a promising avenue for therapy.


'/>"/>

Contact: Sarah Allan
sarah.allan@biologists.com
44-752-876-8387
The Company of Biologists
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Health providers should emphasize breast cancer screening, Wayne State University research finds
2. Leeds researchers test benefit of fish oil in bowel cancer spread
3. Research examines dentists role in painkiller abuse
4. Research reveals new secret weapon for Le Tour
5. The Samuel Waxman Cancer Research Foundation awards more than $3.1 million in grants
6. Georgetown research identifies key reasons racial disparities exist in emergent stroke treatment
7. Group-Think Can Influence Your Memory, Research Shows
8. Journal of Dental Research increases its scientific impact factor
9. AOSSM presents prestigious research awards at annual meeting
10. Fox Chase researchers identify new mechanism used by cells to reverse silenced genes
11. BUSM researchers find herbal medicine treatment reduces inflammation in allergen-induced asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Dr. Diane Walder, one of South Florida’s top cosmetic ... called Ultrashape that is designed to help her patients reduce ... weeks. Ultrashape has been praised by patients as being permanent, ... to other types of external fat reduction. , “If you ... , According to Dr. Walder, Ultrashape works by targeting ...
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5
... Following its recent,merger with Echo Therapeutics, Inc., ... platform-enabled transdermal specialty,therapeutics and diagnostics company, today announced ... Therapeutics, Inc., effective Monday, October 8,2007. In addition, ... Board,ticker symbol will change to "ECTE" and its ...
... ON, Oct. 5 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc., a research-based, technology-driven Canadian biopharmaceutical,company (TSX:BNC), will be ... cattle vaccine,during a: ... ... ...
... 5 Sundance Catalog is proud to,support Susan G. ... end breast,cancer forever by empowering people, ensuring quality care ... of the retail sales price of,the Cherokee "Health" Tee ... a guaranteed minimum donation of $5,000.00. The Cherokee word,for ...
... Edward G. Rendell,today joined the Pennsylvania Dental Association (PDA) ... recognizing October 5, 2007,as Senior Smiles Day in Pennsylvania. ... individual,s overall,health and quality of life," Rendell said in ... adults over the age of sixty-five reside,in the commonwealth ...
... In a significant advancement in the ongoing battle against ... IC-MedTech and other institutions have completed the first ever ... Apatone exploits a new strategy to selectively lower the ... energy production and protect against chemotherapy. This non-toxic ...
... 5 Florida drivers won a major,victory today ... no-fault auto insurance law. The reformed law, which ... both chambers with,overwhelming support. The new changes in ... The Coalition particularly applauded Senator Bill Posey ...
Cached Medicine News:Health News:Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc. 2Health News:Cherokee 'Health' Tee Proceeds Benefit Breast Cancer Research 2Health News:Governor Rendell Declares Senior Smiles Day in Pennsylvania; Goal is to Improve Oral Hygiene for Senior Citizens 2Health News:Researchers complete first clinical trial of Apatone for cancer treatment 2Health News:Researchers complete first clinical trial of Apatone for cancer treatment 3Health News:Hospitals and the Coalition to Protect Florida's Drivers Applaud Lawmakers for Reviving No-Fault Insurance 2
(Date:11/26/2014)... Colo. , Nov. 25, 2014   Heska Corporation ... "Heska" or the "Company"), a provider of advanced veterinary ... Robert Grieve , Executive Chair, will attend The Benchmark ... 2014. The one-on-one conference will be held at The Palmer ... from 8 a.m. to 2:30 p.m. Please email ...
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen (NASDAQ: ... ) today announced that AMAGINE-2 TM , a pivotal, multi-arm ... than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary ... placebo at week 12. Brodalumab 210 mg given every two ... to be superior to Stelara on the primary endpoint of ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... (Nasdaq: OMCL ), a leading provider of system ... quarter and year ended December 31, 2010. ... was $57.3 million, up $1.0 million or 1.7% from the ... from the fourth quarter of 2009.  Revenue for the year ...
... Thoratec Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts, said today that revenues ... over those in fiscal 2009. Results from ... quarter of fiscal 2010 and 2009 exclude contributions from ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full Year 2010 Results 2Omnicell Announces Fourth Quarter and Full Year 2010 Results 3Omnicell Announces Fourth Quarter and Full Year 2010 Results 4Omnicell Announces Fourth Quarter and Full Year 2010 Results 5Omnicell Announces Fourth Quarter and Full Year 2010 Results 6Omnicell Announces Fourth Quarter and Full Year 2010 Results 7Omnicell Announces Fourth Quarter and Full Year 2010 Results 8Omnicell Announces Fourth Quarter and Full Year 2010 Results 9Omnicell Announces Fourth Quarter and Full Year 2010 Results 10Omnicell Announces Fourth Quarter and Full Year 2010 Results 11Omnicell Announces Fourth Quarter and Full Year 2010 Results 12Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 2Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 3Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 4Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 5Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 6Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 7Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 8Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 9Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 10Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 11Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 12Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 13Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 14Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 15
... The ABI PRISM 310 Genetic Analyzer ... for a wide range of sequencing and ... for academic and forensic labs who incorporate ... Genetic Analyzer -- the ideal alternative to ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: